CN1948304A - Heteraryl ring thiosemicarbazone kind compound and its derivative - Google Patents
Heteraryl ring thiosemicarbazone kind compound and its derivative Download PDFInfo
- Publication number
- CN1948304A CN1948304A CN 200510030414 CN200510030414A CN1948304A CN 1948304 A CN1948304 A CN 1948304A CN 200510030414 CN200510030414 CN 200510030414 CN 200510030414 A CN200510030414 A CN 200510030414A CN 1948304 A CN1948304 A CN 1948304A
- Authority
- CN
- China
- Prior art keywords
- dimethyl
- thienyl
- pyridyl
- compound
- thiocarbamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a heteroaryl cyclylic thiosemicarbazone compound and its derivative. Said invention also provides the chemical structure formula of said compound. The tests show that said compound and its derivative have strong action of resisting tumor.
Description
Technical field
The present invention relates to the pharmaceutical chemistry technical field, be specifically related to the isomer configuration of a kind of Heteraryl ring thiosemicarbazone kind compound and derivative thereof.
Background technology
The inventor is once in Chinese patent application (number of accepting 200510027600.8 and 200510028480.3) before this, disclose new (thiosemicarbazone) compound I and derivative thereof and their synthetic method (seeing reaction formula one), and reported that they are to external cancer strain and to the shown good antineoplastic activity that goes out of experiment in the animal body.Experimental result shows to have structure activity relationship very closely between the molecular structure of compound and its tumor-suppression activity in above-mentioned two patent applications of the present invention.
The synthetic method of reaction formula one heterocyclic aryl (thiosemicarbazone) compound I
In the Chinese patent application of the number of accepting 200510027600.8, utilize nuclear magnetic resonance spectrum and high performance liquid chromatography-GC-MS to determine the molecular formula and the universal architecture I of reaction product; This product promptly is the drug sample that is used for experiment in external cancer strain screening and the animal body.In proton nmr spectra, also demonstrate a plurality of compounds and when A ≠ B, have isomer.
Summary of the invention
Technical problem to be solved by this invention is further to prove conclusively the isomer configuration of Heteraryl ring thiosemicarbazone kind compound and derivative.
The invention provides the isomer configuration of Compound I.
In the inventor further studies, utilize the X-ray diffractometer to obtain N, the three-dimensional structure (figure one) of N-dimethyl-N '-[2-(2-thienyl)-2-(2-pyridyl)-1-azepine thiazolinyl]-thiocarbamide (code name is 1).Though according to the general structure of compound 1, this compound exists cis 1A and trans 1B isomer, the X diffractometer is measured and is found that compound 1 is to exist with cis-configuration fully, and active hydrogen is displaced to N
2On.This hydrogen atom has a spot of ionic, simultaneously with pyridine ring on hydrogen atom extremely strong hydrogen bond action is arranged, also have stronger hydrogen bond action (seeing formula two, table 2) with sulphur.Can also observe a big conjugated system-from pyridyl in addition from X-diffraction three-dimensional structure, thienyl is to terminal N4, and the bond distance in the system is all between between singly-bound and pair key, 8 atoms in this system (seeing Table 2) in the same plane basically.
Formula two compounds, 1 cis-trans and tautomer
(dotted line is represented intramolecular hydrogen bond in the molecular structure)
This big conjugated system conforms to 420nM absorption peak in the UV spectrum.In acid, under the alkaline condition, intramolecular hydrogen bond action obtains destroying, thereby has destroyed big conjugated system, and the 420nM absorption peak can move on to 349nM and 392nM respectively in the UV spectrum.
Formula three compounds 1 other tautomer
These results show to have only single configuration under the compound 1 solid situation.This configuration has benefited from the intramolecular hydrogen bond effect and has minimum energy, stable characteristics.
When compound 1 is dissolved in the deuterated solvent, it hydrogen and the nuclear magnetic resonance of carbon spectrum in observe two or more along anti-and tautomer.Except the cis-configuration in solid-state, also exist transconfiguration (formula two, 1B) and other tautomer, 1C for example, 1E, and 1F (seeing formula two, three).Transconfiguration 1B has the intramolecular hydrogen bond effect, accounts for suitable ratio in mixture.No matter be cis 1A or transconfiguration 1B, intramolecularly all has the intramolecular hydrogen bond effect, and this and compound show slightly acid (pH ≈ 6.4) and conform in saturated aqueous solution (rarer, because of solubleness low).
Other tautomer 1C, 1E and 1F also have the possibility of existence; But confirm not contain S-H in the molecule when solid-state through infrared spectra.Simultaneously hydrogen/nuclear magnetic resonance of carbon spectrum is not seen yet and is contained saturated carbon on the heterocycle, so can get rid of tautomer 1F.(COSY-45, HSQC show all in solvent that HMBC) compound 1 mainly comprises 1A and two kinds of isomer of 1B for hydrogen/nuclear magnetic resonance of carbon spectrum and two-dimensional spectrum thereof.
Test is proved conclusively by analysis, and disclosed Heteraryl ring thiosemicarbazone kind compound in the Chinese patent application number of accepting 200510027600.8 and 200510028480.3 exists along anti-and tautomer.They exist with single configuration when solid-state, and for example compound 1 is a cis-configuration, and the crystal of separating out from different solvents (methyl alcohol, ethanol, and second) has same crystalline network, belong to same crystal formation; But in solution, can contain two or more suitable anti-and tautomer simultaneously.Heterocyclic aryl (thiosemicarbazone) compound that other is representative and derivative thereof all may have similar phenomenon because of similar; Their solid-state configuration is listed in the formula four.
Formula four has tautomer heterocyclic aryl (thiosemicarbazone) compound
| 2 | N, N-dimethyl-N '-[2-phenyl-2-(2-pyridyl)-1-azepine thiazolinyl]-thiocarbamide |
| 3 | N, N-dimethyl-N '-[2-(3-pyridyl)-2-(2-pyridyl)-1-azepine thiazolinyl-] thiocarbamide |
| 4 | N, N-dimethyl-N '-[2-(4-pyridyl)-2-(2-pyridyl)-1-azepine thiazolinyl]-thiocarbamide |
| 5 | N-methyl-N-cyclopentyl-N '-[2,2-two (2-pyridyl)-1-azepine thiazolinyl]-thiocarbamide |
In new external and experimentation on animals, compound 1 demonstrates good antineoplastic activity (concrete data are seen example 4 and 5).
The present invention has made further research for the compound structure of above-mentioned Chinese patent application, has determined their cis, trans and tautomer and their effective configuration.
Description of drawings:
Figure one X-light single crystal diffraction structure
Embodiment:
The invention will be further described below in conjunction with specific embodiment.But the present invention is not limited to this.
Embodiment 1 N, N-dimethyl-N '-[2-(2-thienyl)-2-(2-pyridyl)-1-azepine thiazolinyl]-thiocarbamide (1) synthetic
Newly formed 2-thienyl Grignard reagent (preparing with ordinary method from the 2-bromothiophene) and the reaction of 2-itrile group pyridine are promptly got 2-pyridyl-2-thienyl imines, and crude product can be directly used in next step.
At room temperature, dithiocarbonic anhydride (3.8 grams, 50 mmoles) is splashed in the aqueous solution (50 milliliters) of sodium hydroxide (2.4 grams, 60 mmoles) and dimethyl amine (5.45 grams, 33% aqueous solution, 40 mmoles).Reactant stirred after 2 hours, dripped sodium chloroacetate (5.8 grams, the 50 mmoles) aqueous solution (30 milliliters) and continuation and stirred 20 hours.Reactant is acidified to pH=3 with rare HCl solution, throw out is filtered abandon filtrate, gets 4.2 gram intermediates.With this intermediate and sodium hydroxide (0.9 gram, 20 mmoles), hydrazine hydrate (2 milliliters, 85%) and water (12 milliliters) mix, and reflux 4 hours has solid to separate out after the cooling.After the filtration solids is dissolved in hot methylene dichloride, refilters and remove filter residue, concentrated filtrate obtains crude product, again crude product recrystallization in ethanol is got pure product N, N-dimethyl-N '-thiosemicarbazide 0.8 gram.
2-pyridyl-2-thienyl imines (0.9 gram, 5 mmoles) and N, N-dimethyl-N '-thiosemicarbazide (0.6 gram, 5 mmoles) mixes in methylene dichloride (10 milliliters) lining, and stirring adds the dry saturated HCl diethyl ether solution of 0.15ml down and at room temperature stirs and spend the night.After thin layer plate chromatography (TLC) demonstration reacts completely reaction mixture is concentrated into dried.The gained solid promptly gets purified product 1.24 grams, 86% productive rate, fusing point 131-133 ℃ behind the ethyl alcohol recrystallization secondary.
The analysis of embodiment 2 compounds 1 sample
Show that through high performance liquid chromatography-GC-MS detection purity is higher than 99%, mass-to-charge ratio is 289.0[M-1, the negative ion state].
Results of elemental analyses can be as follows: carbon, hydrogen, nitrogen and element sulphur analytical data all conform to theoretical value (difference is no more than 0.3%).Illustrate that this product molecular formula meets C
13H
14N
4S
2
| Analysis project | C | H | N | S |
| Theoretical value (%) | 53.77 | 4.86 | 19.29 | 22.08 |
| Experimental value (%) | 53.79 53.83 | 4.73 5.01 | 19.15 19.06 | 21.87 21.71 |
300,000,000 nucleus magnetic hydrogen spectrum results are as follows: and δ 14.2ppm (S, 0.56H), 13.15 (S, 0.44H), 8.76-8.83 (m, 1H), 7.68-7.90 (m, 3H), 7.25-7.45 (m, 2H), and 7.0-7.20 (m, 1H), [3.44 (S), 3.46 (S), and 3.56 (S, 6H), on three unimodal representative amides nitrogen two methyl because of asymmetric cause split branch and isomer splits branch].(COSY-45, HSQC show all in solvent that HMBC) compound 1 mainly exists with 1A and two kinds of isomeric forms of 1B for hydrogen spectrum and two-dimensional spectrum thereof.
The result is as follows for 300,000,000 nuclear-magnetism carbon spectrum: δ 185.0,181.1, and 151.3,150.6,150.5,148.5,141.8,139.3,137.6,137.2,134.8,134.1,132.8,131.5,128.2,127.2,127.1,126.9,125.4,124.6,124.2,124.0,43.0,42.1,38.9ppm.Wherein contain two groups of double key carbon peaks; Three broad peaks (43.0,42.1,38.9) appear in two methyl carbon, and this is common on amides nitrogen.The carbon stave is bright in solvent, and compound 1 mainly comprises two kinds of isomer.
UV spectrum detected result (being dissolved in the methyl alcohol): 420nm, 351nM, and 277nM.
Embodiment 3 compound 1X ray single crystal structure are analyzed
The sample of compound 1 is cultivated monocrystalline by ethanol, acetonitrile, methanol solvate, and the monocrystalline label that obtains is respectively 1G, 1H and 1Y, and they all have identical water chestnut cylindricality profile, are the transparent outward appearance of dark orange.The x-ray crystal structure assay determination of 1G and 1H shows that molecular formula is C
13H
14N
4S
2, crystal belongs to oblique system, and spacer is: P2/c, 1G is: a=12.325 (3), b=5.591 (1), c=20.137 (4) , β=93.76 (2) °, Z=4, the unit cell parameters a=12.326 of 1H (2), b=5.593 (3), c=20.144 (6) , β=93.76 (2) °; The density that the 1G crystalline structure calculates is 1.393g/cm3, and the density that the 1H crystalline structure calculates is 1.392g/cm3, and the crystalline structure asymmetric cell is all unified a compound molecule, and all there are some hydrogen bonds in this molecule in crystalline structure.The consistence factor 1G of corresponding construction correction is R1=0.0425, wR2=0.1150 reflects (always reflecting several 3078) to 1261 may observe, 1H is R1=0.0459, it is basic identical that wR2=0.1323 reflects (always reflecting number is 3078) two structure elucidation results to 2021 may observe, sees structure determination table and figure as a result for details.(only measure unit cell parameters by methanol solvate crystalline monocrystalline, the undetermined crystalline structure, their unit cell parameters is 1Y:a=12.318 (4), b=5.590 (4), c=20.135 (9) , β=93.71 (3) ° are basic identical with above-mentioned two structures, illustrate that compound 1 all presents with a kind of crystal formation in these three kinds of different solvents.
The crystal data of table 1. compound 1 and structural modifications data.
| Sample encoded empirical formula molecular weight experimental temperature wavelength crystallographic system; Space group cell parameter unit cell volume Z, the number of parameters of integrity degree 2 θ of the reflection number collection data of the reflection sum that the indication range of 2 θ range data of density absorption coefficient F (000) the crystalline size Data Collection of the calculating is collected/uniqueness=27.17 ° of minimum and maximum transmission coefficient structural modifications of absorption correction method total data number/restrictions/total number of parameters F2The last consistent sex factor of match sophistication [to may observe reflection] last consistent sex factor (to all data) the highest remaining difference Fourier peak height and minimum peak valley | 1G C 13H 14N 4S 2290.40 295 (2) K, 0.71073 quadrature, P 2/c a=12.325 (3) b=5.5910 (11) β=93.760 (17) °. c=20.137 (4) 1384.6 (5) 34，1.393Mg/m 30.376mm -127.17 ° of 608 0.40 * 0.30 * 0.25mm, 1.66 to .-15＜=h＜=15; 0＜=k＜=7 ,-1＜=l＜=25 3337/3078[R (int)=0.0320] 100.0% experience absorption correction, 0.9119 and, 0.8642 F2Complete matrix least square method 3,078,/1/,178 0.998 R1=0.0425, wR2=0.1150 R1=0.1809, wR2=0.1559 0.335and-0.355e. -3 |
The bond distance [] of table 2. compound 1 key and bond angle [°]
| S(1)-C(10) S(1)-C(7) S(2)-C(11) N(1)-C(1) N(1)-C(5) N(2)-C(6) N(2)-N(3) N(2)-H(2X) N(3)-C(11) N(4)-C(11) | 1.691(4) 1.726(4) 1.695(4) 1.333(5) 1.345(4) 1.312(4) 1.337(4) 0.877(18) 1.373(4) 1.344(5) |
| N(4)-C(13) N(4)-C(12) C(5)-C(6) C(6)-C(7) C(7)-C(8) C(10)-S(1)-C(7) C(1)-N(1)-C(5) C(6)-N(2)-N(3) C(6)-N(2)-H(2X) N(3)-N(2)-H(2X) N(2)-N(3)-C(11) C(11)-N(4)-C(13) C(11)-N(4)-C(12) C(13)-N(4)-C(12) N(1)-C(1)-C(2) N(1)-C(5)-C(4) N(1)-C(5)-C(6) C(4)-C(5)-C(6) N(2)-C(6)-C(7) N(2)-C(6)-C(5) C(7)-C(6)-C(5) C(6)-C(7)-C(8) C(6)-C(7)-S(1) C(8)-C(7)-S(1) C(9)-C(8)-C(7) N(4)-C(11)-N(3) N(4)-C(11)-S(2) N(3)-C(11)-S(2) | 1.452(5) 1.459(5) 1.492(5) 1.435(4) 1.441(5) 92.1(2) 117.4(3) 124.6(3) 114(2) 121(2) 112.0(3) 122.8(3) 121.5(3) 115.6(3) 123.6(4) 122.5(3) 114.0(3) 123.5(3) 122.1(3) 113.6(3) 124.3(3) 127.1(3) 122.7(3) 110.0(2) 110.3(3) 112.7(3) 122.7(3) 124.6(3) |
The hydrogen bond of table 3. compound 1 [ and ° .]
| D-H...A N(2)-H(2X)...S(2) N(2)-H(2X)...N(1) C(13)-H(13A)...S(1) C(13)-H(13A)...N(3) C(2)-H(2)...S(2)#1 C(1)-H(1)...N(1)#1 | d(D-H) 0.877(18) 0.877(18) 0.96 0.96 0.93 0.93 | d(H...A) 2.37(3) 2.15(3) 2.77 2.21 2.99 2.91 | d(D...A) 2.840(3) 2.620(4) 3.713(4) 2.662(5) 3.618(4) 3.761(5) | ＜(DHA) 114(3) 113(3) 168.6 107.8 125.9 153.4 |
The extracorporeal anti-tumor function research of embodiment 4 compounds 1
Material:
1.MCF-7, the K562 cell
Individual layer or suspend all can, the concentration of making cell suspension is 10-20 * 10
4/ ml.
2.MTT liquid
Concentration 5mg/ml is dissolved in physiological saline, and solution stores 4 ℃, and validity period was 3 weeks.
3. lysate
Contain 10% sodium lauryl sulphate, 5% isopropylcarbinol and 0.02mol/L HCl liquid.
4.RPMI1640 cell culture fluid
Preparation (containing deactivation calf serum and an amount of microbiotic) routinely.
Method:
Get 96 hole microtest plates, the cell suspension 90 μ l/ holes that add certain density (are equivalent to 1-2 * 10
4The cell in/hole), (refer to suspension cell) simultaneously or 37 ℃ put that (monolayer cell) adds different concns reagent 10 μ l/ holes behind the 4-6hr, every retaining concentration is established three multiple holes, negative control hole adds to cultivate and also replaces.In addition, establish the zero point hole of the blank 1-2 sky in acellular no reagent 100 μ l pure culture liquid/holes as demodulating apparatus simultaneously, vibration makes mixing then, places 37 ℃, 5%CO
2Incubator adds MTT liquid 20 μ l/ holes after (48 or 72hr) again, after continuing to cultivate 4hr, adds lysate 100 μ l/ holes, in placing 37 ℃ of incubators, next day, surveys the optical density(OD) (can adopt the DG3022 enzyme-linked immunosorbent assay instrument) in each hole with the A570 wavelength.Each grade test solution hole average and negative control value relatively get the percent inhibition (establishing certain density standard antitumour drug simultaneously as positive control) of each grade concentration.Calculation formula is:
IC％＝(C-T)/C×100％
T is the negative control group OD of a test solution group OD value C value
According to each IC% that detects each grade of liquid concentration, try to achieve IC then with regression curve
50Value.
Effect assessment:
Represent (IC with half-inhibition concentration
50Value), synthetic drug IC
50＜10 μ g/ml think antitumor restraining effect.
The experiment in vitro result of 1 pair of above-mentioned tumour cell of table 4 compound is as follows:
| Cell strain | IC50(ug/ml) |
| MCF-7 | 0.18 |
| K562 | 0.62 |
Embodiment 5. compounds 1 mouse inhibition test
One, test objective
With murine melanoma B16 is model, and the antitumor action of compound 1 is studied.
Two, content of the test
Intravenous injection compound 1 is studied its growth-inhibiting effect to murine melanoma B16
1, test sample
Sample: compound 1 is provided by SUNDIA company.
Reference substance: Cyclophosphamide for injection (CTX), Hualian Pharmaceutical Co., Ltd., Shanghai, lot number: 020806.
2, compound method
Sample: with 2: 1 ethanol and soil temperature-80 ultrasonic wave heating hydrotropy, be formulated as desired concn with physiological saline again when compound 1 uses.
Reference substance: use physiological saline solution during Cyclophosphamide for injection (CTX) preparation.
3, animal and knurl strain
50 of C57BL/6 mouse, female, body weight 18 ± 1g, limited liability company provides by the Si Laike laboratory animal, conformity certification: SCXK (Shanghai) 2002-0015.
The knurl strain: mouse B16 melanoma solid-type, gone down to posterity by pharmacological room of Shanghai Institute of Pharmaceutical Industry and to keep.
4, test method
Get the B16 murine melanoma solid tumor of growth animated period, cut open under the aseptic condition and get the knurl piece, ground evenly by 1: 5, press 0.2ml/ and only give the subcutaneous vaccination of mouse armpit with physiological saline.At random be divided into 5 group with mouse next day, 10 every group.According to experimental result in the past, compound 1 intravenously administrable dosage be set be 2,0.5,0.0625mg/kg experimentizes.The reference substance endoxan adopts the abdominal injection administration, and dosage is 30mg/kg * 7d.
Other establishes control group.
Animal inoculation pvaccination begins by the body weight administration next day, intravenous injection 0.5ml/20g, and continuous 7 days, put to death on the 15th day the inoculation back, gets the knurl piece and weigh, and calculates tumour inhibiting rate.The result judges according to following formula:
4, result
Each treated animal of experimental session there is no death.
Table 5,1 pair of melanomatous restraining effect of B16 of compound (X ± SD)
| Group | Dosage mg/kg | Route of administration | Number of animals rises/end | Body weight plays (g) | Body weight (getting knurl) (g) | Knurl heavy (g) | Tumour inhibiting rate % |
| Compound 1 | 2 | i.v×7 | 10/10 | 18.43±0.52 | 20.90±2.03 | 0.15±0.06 | 96.19 |
| 0.5 | i.v×7 | 10/10 | 18.37±0.31 | 21.69±1.66 | 0.37±0.11 | 90.59 | |
| 0.0625 | i.v×7 | 10/10 | 18.37±0.39 | 21.45±1.42 | 1.37±0.42 | 65.30 | |
| CTX | 30 | i.p×7 | 10/10 | 18.27±0.19 | 19.75±1.56 | 0.68±0.21 | 82.61 |
| Control group (coordinative solvent) | 25 ml/kg | i.v×7 | 10/10 | 18.33±0.35 | 22.49±1.39 | 3.93±0.99 |
Claims (7)
1, a kind of formula I Heteraryl ring thiosemicarbazone kind compound and derivative thereof with antitumor action is characterized in that they are cis-configuration and have the trans and tautomer of cis when liquid state when solid-state:
2, a kind of N, N-dimethyl-N '-[2-(2-thienyl)-2-(2-pyridyl)-1-azepine thiazolinyl]-thiocarbamide is characterized in that it has following X-light single crystal diffraction structure; Data:
Empirical formula C
13H
14N
4S
2
Molecular weight 290.40
Experimental temperature 295 (2) K
Wavelength 0.71073
Crystallographic system, spacer quadrature, P2/c
Unit cell parameters a=12.325 (3)
b＝5.5910(11)β＝93.760(17)°.
c＝20.137(4)
Unit cell volume 1384.6 (5)
3
Z, the density 4 of calculating, 1.393Mg/m
3
Uptake factor 0.376mm
-1
F(000) 608
Crystalline size 0.40 * 0.30 * 0.25mm
27.17 ° of 2 θ scopes, 1.66 to of data gathering.
The indication range of data-15＜=h＜=15,0＜=k＜=7 ,-1＜=1＜=25
3337/3078[R (int)=0.0320 is counted in the reflection of the reflection sum/uniqueness of collecting]
Integrity degree 2 θ of collection data=27.17 ° 100.0%
Absorption correction experience absorption correction
Minimum and maximum transmission coefficient 0.9119 and 0.8642
Structural modifications method F
2The complete matrix least square method
The number of parameters of total data number/restriction/total number of parameters 3078/1/178
F
2Match sophistication 0.998
Last consistent sex factor [to the may observe reflection] R1=0.0425, wR2=0.1150
Last consistent sex factor (to all data) R1=0.1809, wR2=0.1559
The highest remaining difference Fourier peak height and minimum peak valley 0.335 and-0.355e.
-3
3, a kind of N according to claim 2, N-dimethyl-N '-[2-(2-thienyl)-2-(2-pyridyl)-1-azepine thiazolinyl]-thiocarbamide is characterized in that this compound has tautomer when liquid state, has cis-configuration 1A and transconfiguration 1B:
4, a kind of N according to claim 2, N-dimethyl-N '-[2-(2-thienyl)-2-(2-pyridyl)-1-azepine thiazolinyl]-thiocarbamide is characterized in that this compound is cis-configuration when solid-state.
5, a kind of N, the synthetic method of N-dimethyl-N '-[2-(2-thienyl)-2-(2-pyridyl)-1-azepine thiazolinyl]-thiocarbamide is characterized in that this compound is cis-configuration when solid-state, its synthetic method comprises the following steps:
(1) preparation 2-pyridyl-2-thienyl imines:
2 thienyl Grignard reagents and the reaction of 2-itrile group pyridine make 2-pyridyl-2-thienyl imines;
(2) preparation N, N-dimethyl-N '-thiosemicarbazide:
At room temperature, dithiocarbonic anhydride is splashed in the aqueous solution of sodium hydroxide and dimethyl amine, stir after 2 hours, in reactant, drip the sodium chloroacetate aqueous solution, continue to stir 20 hours, reaction is finished, be acidified to pH 3 with dilute hydrochloric acid, filter, abandon filtrate, this intermediate product and sodium hydroxide, hydrazine hydrate and water mix, reflux 4 hours, and solid is separated out in cooling, filter, to obtain solid and be dissolved in hot methylene dichloride, remove by filter filter residue, filtrate concentrate crude product, recrystallization gets N in ethanol again, N-dimethyl-N '-thiosemicarbazide;
(3) preparation N, N-dimethyl-N '-[2-(2-thienyl)-2-(2-pyridyl)-1-azepine thiazolinyl]-thiocarbamide;
2-pyridyl-2-thienyl imines and N, N-dimethyl-N '-thiosemicarbazide stirred liquid, and after the thin-layer chromatography demonstration reacted completely, reactant was concentrated into dried, get N with ethyl alcohol recrystallization again, N-dimethyl-N '-[2-(2-thienyl)-2-(2-pyridyl)-1-azepine thiazolinyl]-thiocarbamide.
6, a kind of N that when solid-state, is cis-configuration, the application of N-dimethyl-N '-[2-(2-thienyl)-2-(2-pyridyl)-1-azepine thiazolinyl]-thiocarbamide in the preparation antitumor drug.
7. one kind has cis when liquid state, the N of trans or other tautomer, the application of N-dimethyl-N '-[2-(2-thienyl)-2-(2-pyridyl)-1-azepine thiazolinyl]-thiocarbamide in the preparation antitumor drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200510030414XA CN100506819C (en) | 2005-10-12 | 2005-10-12 | Heteraryl ring thiosemicarbazone kind compound and its derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200510030414XA CN100506819C (en) | 2005-10-12 | 2005-10-12 | Heteraryl ring thiosemicarbazone kind compound and its derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1948304A true CN1948304A (en) | 2007-04-18 |
| CN100506819C CN100506819C (en) | 2009-07-01 |
Family
ID=38017942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200510030414XA Active CN100506819C (en) | 2005-10-12 | 2005-10-12 | Heteraryl ring thiosemicarbazone kind compound and its derivative |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100506819C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD4132C1 (en) * | 2010-12-13 | 2012-05-31 | Государственный Университет Молд0 | Di(µ-S)-bis{chloro-[phenyl(pyridine-2-yl)methanone-thiosemicarbazonato(1-)]-copper} manifesting the property of inhibiting the proliferation of mammary cancer T-47D cells |
| CN104177288A (en) * | 2013-05-23 | 2014-12-03 | 中国人民解放军军事医学科学院毒物药物研究所 | Selenosemicarbazone derivative, and pharmaceutical composition and application thereof |
-
2005
- 2005-10-12 CN CNB200510030414XA patent/CN100506819C/en active Active
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD4132C1 (en) * | 2010-12-13 | 2012-05-31 | Государственный Университет Молд0 | Di(µ-S)-bis{chloro-[phenyl(pyridine-2-yl)methanone-thiosemicarbazonato(1-)]-copper} manifesting the property of inhibiting the proliferation of mammary cancer T-47D cells |
| CN104177288A (en) * | 2013-05-23 | 2014-12-03 | 中国人民解放军军事医学科学院毒物药物研究所 | Selenosemicarbazone derivative, and pharmaceutical composition and application thereof |
| CN104177288B (en) * | 2013-05-23 | 2020-05-01 | 中国人民解放军军事医学科学院毒物药物研究所 | Semicarbazone derivatives, pharmaceutical compositions and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100506819C (en) | 2009-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109054826B (en) | Red fluorescent carbon quantum dot and preparation method and application thereof | |
| CN101633640B (en) | Naphthalimide derivative | |
| CN105601635B (en) | Ba Ruike is for Buddhist nun phosphatic A crystal formations, H crystal form and I crystal and preparation method thereof | |
| CN101058820A (en) | Method of catalytically synthesizing alpha-monolinolenin by using immobilization lipase | |
| CN1810816A (en) | Tenoforv monoester compounds with HIV-1/HBV virus copying inhibiting activity | |
| CN1850779A (en) | Beta-element nitrogenous derivative, and its preparing method and use | |
| CN107266348B (en) | Preparation, structure and the purposes of 4-acetylbiphenyl hydrazone -3- indolecarboxaldehyde Schiff base | |
| CN101638389B (en) | Polyamine derivative containing naphthalimide structure, preparation method and application thereof | |
| CN1948304A (en) | Heteraryl ring thiosemicarbazone kind compound and its derivative | |
| CN1014990B (en) | 5-pyrimidinecarboxamides and treatment of leukemia and tumors therewith | |
| JPS61171496A (en) | Platinum complex of aliphatic tricarboxylic acid | |
| CN103864638B (en) | A kind of benzoic acid derivative and its preparation method and application | |
| CN1218949C (en) | Artemisine arylether derivatives and their preparing process | |
| CN1268630C (en) | Synthesis for compound of diamine bridge linking ortho phenanthroline hydrous lanthanum (III) and anti-cancer activity thereof | |
| CN101654459A (en) | Pyrrole [2, 1-b] thiazolium compound and preparation method and anti-tumor application thereof | |
| CN102584670B (en) | Indole-3-formaldehyde shrinkage phenylenediamine bis-schiff base and preparation method thereof | |
| CN1274694C (en) | Lanthanum amino acid complex and its preparing process and application | |
| CN1283640C (en) | Ramification in albocarbon category and application in anoxia system | |
| CN1187357C (en) | Calcarisporin B1 and extracting method and use in anti-tumor medicine | |
| CN110240611B (en) | Preparation method and application of photosensitizer targeting EGFR (epidermal growth factor receptor) over-expression tumor cell endoplasmic reticulum | |
| CN114031635B (en) | Difluoroborocurcumin derivative and preparation method and application thereof | |
| CN111138361B (en) | Substituted phenoxy-2-azabicyclo [3.2.1] octane compounds and preparation method and application thereof | |
| CN108997420B (en) | Synthesis method of triphenyl-n- (colchicine amido) butyl phosphonium chloride compound and application of triphenyl-n- (colchicine amido) butyl phosphonium chloride compound in antitumor drugs | |
| CN108383795B (en) | 1-benzimidazole-N-amide derivative and preparation method thereof | |
| CN1094410A (en) | Hydroxy cholesterol succinic acid monoester and salt thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20070330 Address after: Edison Shanghai Road, Zhangjiang High Tech Park of Pudong No. 326 30211 room Applicant after: Challenge Medical Sci. & Tech. (Shanghai) Co., Ltd. Address before: Shanghai Zhangjiang High Tech Park of Pudong Cailun road 720 Lane 2 building room 504 Applicant before: Sundia MediTech (Shanghai) Company Ltd. |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Suzhou Hong Qing Pharmaceutical Co., Ltd. Assignor: Challenge Medical Sci. & Tech. (Shanghai) Co., Ltd. Contract record no.: 2010990000955 Denomination of invention: N, N-, two methyl -N '- [2- (2- thiophene) -2- (2- pyridyl) -1- aza] - thiourea Granted publication date: 20090701 License type: Exclusive License Open date: 20070418 Record date: 20101206 |
|
| ASS | Succession or assignment of patent right |
Owner name: SUZHOU HONGSEN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CHALLENGE MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD. Effective date: 20110602 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201203 ROOM 3021-1, NO. 326, EDISON ROAD, ZHANGJIANG HIGH-TECH. PARK, PUDONG, SHANGHAI TO: 215400 XIEXIN ROAD, PORT DEVELOPMENT ZONE, TAICANG PORT, SUZHOU CITY, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110602 Address after: GCL road Taicang Jiangsu province 215400 city port Suzhou Port Development Zone Patentee after: Suzhou Hong Qing Pharmaceutical Co., Ltd. Address before: 201203, room 326, 3021-1 Edison Road, Zhangjiang hi tech park, Shanghai, Pudong Patentee before: Challenge Medical Sci. & Tech. (Shanghai) Co., Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: SUZHOU HOMESUN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SUZHOU HONGSEN PHARMACEUTICAL CO., LTD. Effective date: 20120130 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 215400 SUZHOU, JIANGSU PROVINCE TO: 215433 SUZHOU, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20120130 Address after: GCL road Taicang Jiangsu province 215433 city port Suzhou Port Development Zone Patentee after: Suzhou Homesun Pharmaceutical Co., Ltd. Address before: GCL road Taicang Jiangsu province 215400 city port Suzhou Port Development Zone Patentee before: Suzhou Hong Qing Pharmaceutical Co., Ltd. |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: GCL road Taicang Jiangsu province 215433 city port Suzhou Port Development Zone Patentee after: Suzhou Hong Sen pharmaceutical Limited by Share Ltd Address before: GCL road Taicang Jiangsu province 215433 city port Suzhou Port Development Zone Patentee before: Suzhou Homesun Pharmaceutical Co., Ltd. |